Table 1.
Baseline clinicopathologic characteristics of 146 metastatic castration resistant prostate cancer patients
| Characteristics | Values |
|---|---|
| Age (year), median (range) | 73.1 (53.5–89.2) |
| PSA (ng ml−1), median (range) | 74.5 (2.9–340.9) |
| Hemoglobin (g l−1), median (range) | 124.0 (40.0–161.0) |
| ALP (U l−1), median (range) | 88.6 (36.0–719.0) |
| LDH (U l−1), median (range) | 197.0 (47.0–752.0) |
| ALB (U l−1), median (range) | 41.0 (22.0–76.0) |
| Duration of previous hormonal therapy (month), median (range) | 16.0 (1.0–183.0) |
| ECOG performance status, n (%) | |
| 0–1 | 131 (89.7) |
| ≥2 | 15 (10.3) |
| Stage at initial diagnosis, n (%) | |
| M0 | 13 (8.9) |
| M1 | 133 (91.1) |
| Gleason score of primary lesion, n (%) | |
| 5–7 | 39 (26.7) |
| 8–10 | 107 (73.3) |
| Site of metastatic diseasea, n (%) | |
| Bone | 135 (92.5) |
| Lymph node | 27 (18.5) |
| Liver | 6 (4.1) |
| Lung | 5 (3.4) |
| Brain | 2 (1.4) |
| Other soft tissue | 2 (1.4) |
| Extent of disease, n (%) | |
| 0–5 metastatic sites | 91 (62.3) |
| >5 metastatic sites | 55 (37.7) |
| Previous therapies, n (%) | |
| Flutamide | 103 (70.5) |
| Bicalutamide | 139 (95.2) |
| Estrogen | 17 (11.6) |
| Docetaxel chemotherapy | 43 (29.5) |
a121 patients developed multi-organ metastasis. PSA: prostate-specific antigen; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; ALB: albumin; ECOG: Eastern Cooperative Oncology Group